Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma

Table 1 Proliferating cell nuclear antigen and E-cadherin labeling indexes in normal gastric tissues and diseased tissues

Tissue type	Number of cases	PCNA labeling index	E-cadherin labeling index
Normal gastric tissue	40	1.37 ± 0.32	22.34 ± 6.23
Intestinal metaplasia	38	11.53 ± 3.38	13.92 ± 4.34
Dysplasia	42	14.34 ± 4.71	7.84 ± 2.08
Gastric cancer	66	44.50 ± 9.85	1.68 ± 0.47
F-value	-	4.170	5.181
P-value	-	0.018	0.002
Comparison of gastric cancer and dysplasia
Q-value		-18.519	23.204
P-value		0.000	0.000

PCNA: Proliferating cell nuclear antigen.

Table 2 Proliferating cell nuclear antigen and E-cadherin expression in the two groups

Group	No. of cases	PCNA				E-cadherin
		-	+	++	+++	-	+	++	+++
Normal group	40	29	6	4	1	5	15	11	9
Gastric cancer group	66	16	11	17	22	45	11	7	3
Z-value	-	-5.231				-4.982
P-value	-	0.000				0.000

PCNA: Proliferating cell nuclear antigen.

Table 3 Relationship between proliferating cell nuclear antigen and E-cadherin expression and clinicopathological characteristics of gastric cancer patients

Clinicopathological characteristic	No. of cases	PCNA		E-cadherin
		Positive	P value	Positive	P value
Gender			0.073		0.340
Male	45	37		16
Female	21	13		5
Age (yr)			0.319		0.140
≥ 60	40	32		10
< 60	26	18		11
Lymph node metastasis			0.039		0.000
Yes	42	36		7
Non	24	14		14
Degree of differentiation			0.278		0.065
Medium and low differentiation	42	30		10
High differentiation	24	20		11
T stage			0.003		0.568
T1/T2	25	14		9
T3/T4	41	36		12

PCNA: Proliferating cell nuclear antigen.

Table 4 Analysis of clinicopathological factors that influence the prognosis of patients with gastric cancer

Variable	Log-rank univariate analysis	Cox regression multivariate analysis
	P value	P value	RR (95%CI)
Gender	0.285	-	-
Age	0.128	-	-
Lymph node metastasis	0.000	0.055	4.369 (0.967-19.733)
Degree of differentiation	0.268	-	-
T stage	0.004	0.000	17.556 (5.343-57.680)
PCNA	0.003	0.000	28.786 (5.088-162.853)
E-cadherin	0.021	0.005	0.174 (0.051-0.598)

Table 5 Evaluation of gastric cancer patient survival by proliferating cell nuclear antigen and E-cadherin

Indicators	Survival time <3 yr	Survival time >3 yr	Sensitivity	Specificity	Accuracy
PCNA			93.33%	38.89%	0.64
Positive	28	22
Negative	2	14
E-cadherin			80.0%	41.67%	0.59
Positive	6	15
Negative	24	21
The combination of both (PCNA[+] and E-cadherin[-])			80.0%	66.67%	0.73
Positive	24	12
Negative	6	24

PCNA: Proliferating cell nuclear antigen.